
Global Targeted Drugs for Parkinson's Disease Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Targeted Drugs for Parkinson's Disease market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Targeted Drugs for Parkinson's Disease market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Targeted Drugs for Parkinson's Disease market include Acadia Pharmaceuticals Inc., Supernus Pharmaceuticals, UCB, Kyowa Kirin and Sumitomo Pharma Co., Ltd., etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Targeted Drugs for Parkinson's Disease, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Targeted Drugs for Parkinson's Disease, also provides the value of main regions and countries. Of the upcoming market potential for Targeted Drugs for Parkinson's Disease, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Targeted Drugs for Parkinson's Disease revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Targeted Drugs for Parkinson's Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Targeted Drugs for Parkinson's Disease company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Targeted Drugs for Parkinson's Disease Segment by Company
Acadia Pharmaceuticals Inc.
Supernus Pharmaceuticals
UCB
Kyowa Kirin
Sumitomo Pharma Co., Ltd.
Targeted Drugs for Parkinson's Disease Segment by Type
Patch
Capsule
Other
Targeted Drugs for Parkinson's Disease Segment by Application
Hospital
Clinic
Other
Targeted Drugs for Parkinson's Disease Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Targeted Drugs for Parkinson's Disease status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Targeted Drugs for Parkinson's Disease key companies, revenue, market share, and recent developments.
3. To split the Targeted Drugs for Parkinson's Disease breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Targeted Drugs for Parkinson's Disease market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Targeted Drugs for Parkinson's Disease significant trends, drivers, influence factors in global and regions.
6. To analyze Targeted Drugs for Parkinson's Disease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Parkinson's Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Parkinson's Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Parkinson's Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeted Drugs for Parkinson's Disease industry.
Chapter 3: Detailed analysis of Targeted Drugs for Parkinson's Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Targeted Drugs for Parkinson's Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Targeted Drugs for Parkinson's Disease in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Targeted Drugs for Parkinson's Disease market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Targeted Drugs for Parkinson's Disease market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Targeted Drugs for Parkinson's Disease market include Acadia Pharmaceuticals Inc., Supernus Pharmaceuticals, UCB, Kyowa Kirin and Sumitomo Pharma Co., Ltd., etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Targeted Drugs for Parkinson's Disease, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Targeted Drugs for Parkinson's Disease, also provides the value of main regions and countries. Of the upcoming market potential for Targeted Drugs for Parkinson's Disease, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Targeted Drugs for Parkinson's Disease revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Targeted Drugs for Parkinson's Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Targeted Drugs for Parkinson's Disease company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Targeted Drugs for Parkinson's Disease Segment by Company
Acadia Pharmaceuticals Inc.
Supernus Pharmaceuticals
UCB
Kyowa Kirin
Sumitomo Pharma Co., Ltd.
Targeted Drugs for Parkinson's Disease Segment by Type
Patch
Capsule
Other
Targeted Drugs for Parkinson's Disease Segment by Application
Hospital
Clinic
Other
Targeted Drugs for Parkinson's Disease Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Targeted Drugs for Parkinson's Disease status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Targeted Drugs for Parkinson's Disease key companies, revenue, market share, and recent developments.
3. To split the Targeted Drugs for Parkinson's Disease breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Targeted Drugs for Parkinson's Disease market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Targeted Drugs for Parkinson's Disease significant trends, drivers, influence factors in global and regions.
6. To analyze Targeted Drugs for Parkinson's Disease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Parkinson's Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Parkinson's Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Parkinson's Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeted Drugs for Parkinson's Disease industry.
Chapter 3: Detailed analysis of Targeted Drugs for Parkinson's Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Targeted Drugs for Parkinson's Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Targeted Drugs for Parkinson's Disease in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
199 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Targeted Drugs for Parkinson's Disease Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Targeted Drugs for Parkinson's Disease Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Targeted Drugs for Parkinson's Disease Market Dynamics
- 2.1 Targeted Drugs for Parkinson's Disease Industry Trends
- 2.2 Targeted Drugs for Parkinson's Disease Industry Drivers
- 2.3 Targeted Drugs for Parkinson's Disease Industry Opportunities and Challenges
- 2.4 Targeted Drugs for Parkinson's Disease Industry Restraints
- 3 Targeted Drugs for Parkinson's Disease Market by Company
- 3.1 Global Targeted Drugs for Parkinson's Disease Company Revenue Ranking in 2024
- 3.2 Global Targeted Drugs for Parkinson's Disease Revenue by Company (2020-2025)
- 3.3 Global Targeted Drugs for Parkinson's Disease Company Ranking (2023-2025)
- 3.4 Global Targeted Drugs for Parkinson's Disease Company Manufacturing Base and Headquarters
- 3.5 Global Targeted Drugs for Parkinson's Disease Company Product Type and Application
- 3.6 Global Targeted Drugs for Parkinson's Disease Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Targeted Drugs for Parkinson's Disease Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Targeted Drugs for Parkinson's Disease Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Targeted Drugs for Parkinson's Disease Market by Type
- 4.1 Targeted Drugs for Parkinson's Disease Type Introduction
- 4.1.1 Patch
- 4.1.2 Capsule
- 4.1.3 Other
- 4.2 Global Targeted Drugs for Parkinson's Disease Sales Value by Type
- 4.2.1 Global Targeted Drugs for Parkinson's Disease Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Targeted Drugs for Parkinson's Disease Sales Value by Type (2020-2031)
- 4.2.3 Global Targeted Drugs for Parkinson's Disease Sales Value Share by Type (2020-2031)
- 5 Targeted Drugs for Parkinson's Disease Market by Application
- 5.1 Targeted Drugs for Parkinson's Disease Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Targeted Drugs for Parkinson's Disease Sales Value by Application
- 5.2.1 Global Targeted Drugs for Parkinson's Disease Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Targeted Drugs for Parkinson's Disease Sales Value by Application (2020-2031)
- 5.2.3 Global Targeted Drugs for Parkinson's Disease Sales Value Share by Application (2020-2031)
- 6 Targeted Drugs for Parkinson's Disease Regional Value Analysis
- 6.1 Global Targeted Drugs for Parkinson's Disease Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Targeted Drugs for Parkinson's Disease Sales Value by Region (2020-2031)
- 6.2.1 Global Targeted Drugs for Parkinson's Disease Sales Value by Region: 2020-2025
- 6.2.2 Global Targeted Drugs for Parkinson's Disease Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Targeted Drugs for Parkinson's Disease Sales Value (2020-2031)
- 6.3.2 North America Targeted Drugs for Parkinson's Disease Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Targeted Drugs for Parkinson's Disease Sales Value (2020-2031)
- 6.4.2 Europe Targeted Drugs for Parkinson's Disease Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Targeted Drugs for Parkinson's Disease Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Targeted Drugs for Parkinson's Disease Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Targeted Drugs for Parkinson's Disease Sales Value (2020-2031)
- 6.6.2 South America Targeted Drugs for Parkinson's Disease Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Targeted Drugs for Parkinson's Disease Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Targeted Drugs for Parkinson's Disease Sales Value Share by Country, 2024 VS 2031
- 7 Targeted Drugs for Parkinson's Disease Country-level Value Analysis
- 7.1 Global Targeted Drugs for Parkinson's Disease Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Targeted Drugs for Parkinson's Disease Sales Value by Country (2020-2031)
- 7.2.1 Global Targeted Drugs for Parkinson's Disease Sales Value by Country (2020-2025)
- 7.2.2 Global Targeted Drugs for Parkinson's Disease Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.7.2 France Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.14.2 China Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.17.2 India Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Targeted Drugs for Parkinson's Disease Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Targeted Drugs for Parkinson's Disease Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Targeted Drugs for Parkinson's Disease Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Acadia Pharmaceuticals Inc.
- 8.1.1 Acadia Pharmaceuticals Inc. Comapny Information
- 8.1.2 Acadia Pharmaceuticals Inc. Business Overview
- 8.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
- 8.1.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Product Portfolio
- 8.1.5 Acadia Pharmaceuticals Inc. Recent Developments
- 8.2 Supernus Pharmaceuticals
- 8.2.1 Supernus Pharmaceuticals Comapny Information
- 8.2.2 Supernus Pharmaceuticals Business Overview
- 8.2.3 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
- 8.2.4 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Product Portfolio
- 8.2.5 Supernus Pharmaceuticals Recent Developments
- 8.3 UCB
- 8.3.1 UCB Comapny Information
- 8.3.2 UCB Business Overview
- 8.3.3 UCB Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
- 8.3.4 UCB Targeted Drugs for Parkinson's Disease Product Portfolio
- 8.3.5 UCB Recent Developments
- 8.4 Kyowa Kirin
- 8.4.1 Kyowa Kirin Comapny Information
- 8.4.2 Kyowa Kirin Business Overview
- 8.4.3 Kyowa Kirin Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
- 8.4.4 Kyowa Kirin Targeted Drugs for Parkinson's Disease Product Portfolio
- 8.4.5 Kyowa Kirin Recent Developments
- 8.5 Sumitomo Pharma Co., Ltd.
- 8.5.1 Sumitomo Pharma Co., Ltd. Comapny Information
- 8.5.2 Sumitomo Pharma Co., Ltd. Business Overview
- 8.5.3 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Revenue and Gross Margin (2020-2025)
- 8.5.4 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Product Portfolio
- 8.5.5 Sumitomo Pharma Co., Ltd. Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.